Spots Global Cancer Trial Database for Subjects With Advanced or Metastatic Solid Tumor Malignancies

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Subjects With Advanced or Metastatic Solid Tumor Malignancies

Official Title: A Phase 1, Multicenter Tolerability and Pharmacokinetic Study of Ascending Continuous Oral Doses of XT-0528 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Study ID: NCT05474859

Conditions

Metastatic Solid Tumor

Advanced Solid Tumor

Interventions

XT-0528

Study Description

Brief Summary: This study is an open-label, Phase 1, multicenter, continuous dose escalation study of XT-0528 in adult subjects with Advanced or Metastatic Solid Tumor Malignancies. The study will consist of 4 periods: Screening Period (up to 28 days prior to Cycle 1 Day 1) Safety Run-in Period (Cycle 1; continuous dosing on Days 1-21 of 28-day cycle) Continuous Dosing Period (Cycle 2 and beyond; continuous dosing on Days 1-28 of 28-day cycle) Safety Follow-up Period (30 days post-last dose).

Detailed Description: Primary Objective * To determine the dose recommended for future Phase 2 studies (RP2D) that maximally suppresses T helper 17 (TH17) cell activities with an absence of dose limiting toxicity (DLT) and without exceeding the maximum tolerable dose (MTD). Secondary Objective * To establish the pharmacokinetics (PK) of orally administered XT-0528. * To observe subjects for evidence of the antitumor activity of XT-0528.